Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Alkermes Response to Avadel Announcement

PR Newswire 1 day ago

Avadel Receives Unsolicited Proposal from Lundbeck

GlobeNewswire 1 day ago

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

PR Newswire 3 days ago

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire 8 days ago

FORM 8.1(a) & (b) (Opening Position Disclosure)

PR Newswire 10 days ago

Alkermes plc Reports Third Quarter 2025 Financial Results

PR Newswire October 28, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq - AVDL), Middlefield Banc Corp. (Nasdaq - MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA)

GlobeNewswire October 22, 2025

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

PR Newswire October 22, 2025

Alkermes to Report Third Quarter Financial Results on October 28, 2025

PR Newswire October 20, 2025

Alkermes Appoints Joshua Reed as Chief Financial Officer

PR Newswire September 12, 2025

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

PR Newswire September 11, 2025

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

PR Newswire September 8, 2025

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

PR Newswire August 25, 2025

Alkermes plc Reports Second Quarter 2025 Financial Results

PR Newswire July 29, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

PR Newswire July 21, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025

PR Newswire July 15, 2025

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

PR Newswire June 2, 2025

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

PR Newswire June 2, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

PR Newswire May 29, 2025

Alkermes plc Reports First Quarter 2025 Financial Results

PR Newswire May 1, 2025